

# **Identification of AnnexinA1 as an endogenous regulator of RhoA, and its role in the pathophysiology and experimental therapy of type-2 diabetes.**

**Gareth S.D. Purvis<sup>1\*</sup>, Massimo Collino<sup>2\*</sup>, Rodrigo Azevedo Loiola<sup>1</sup>, Andrea Baragetti<sup>3,4</sup>, Fausto Chiazza<sup>2</sup>, Martina Brovelli<sup>1,3,4</sup>, Madeeha H. Sheikh<sup>1</sup>, Debora Collotta<sup>2</sup>, Alessia Cento<sup>5</sup>, Raffaella Mastrocola<sup>5</sup>, Manuela Aragno<sup>6</sup>, Juan C. Cutrin<sup>6</sup>, Chris Reutelingsperger<sup>7</sup>, Liliana Grigore<sup>4,8</sup>, Alberico L Catapano<sup>3</sup>, Magdi M Yaqoob<sup>1</sup>, Giuseppe Danilo Norata<sup>3,4</sup>, Egle Solito<sup>\*1,9</sup> and Christoph Thiernemann<sup>\*1</sup>**

<sup>1</sup>Queen Mary University of London, Bart's and The London School of Medicine & Dentistry, The William Harvey Research Institute, Charterhouse Square, London, United Kingdom.

<sup>2</sup>University of Turin, Department of Drug Science and Technology, Turin, Italy.

<sup>3</sup>Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy.

<sup>4</sup>Centro SISA per lo studio del'Aterosclerosi, Bassini Hospital, Cinisello Balsamo

<sup>5</sup>Dept. of Clinical and Biological Sciences, University of Turin, Italy;

<sup>6</sup>Dept. of Molecular Biotechnology and Sciences for the Health, University of Turin, Italy;

<sup>7</sup>Maastricht University, Cardiovascular Research Institute, Maastricht, The Netherlands

<sup>8</sup>IRCCS Multimedica, Sesto San Giovanni, Italy.

<sup>9</sup> Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli "Federico II", Napoli, Italy

## **Correspondence**

Dr Egle Solito and Professor Christoph Thiernemann

Queen Mary University of London, Barts and The London School of Medicine & Dentistry, The William Harvey Research Institute, Charterhouse Square, London, EC1M 6BQ, UK. Tel: 020 7882 2107

[e.solito@qmul.ac.uk](mailto:e.solito@qmul.ac.uk); [c.thiernemann@qmul.ac.uk](mailto:c.thiernemann@qmul.ac.uk)

## Abstract

Annexin A1 (ANXA1) is an endogenously produced anti-inflammatory protein, which plays an important role in the pathophysiology of diseases associated with chronic inflammation. We demonstrate that patients with type-2 diabetes have increased plasma levels of ANXA1 when compared to normoglycemic subjects. Plasma ANXA1 positively correlated with fatty liver index and elevated plasma cholesterol in patients with type-2 diabetes, suggesting a link between aberrant lipid handling and ANXA1. Using a murine model of high fat diet (HFD)-induced insulin resistance, we then investigated (a) the role of endogenous ANXA1 in the pathophysiology of HFD-induced insulin resistance using ANXA1<sup>-/-</sup> mice, and (b) the potential use of hrANXA1 as a new therapeutic approach for experimental diabetes and its microvascular complications. We demonstrate that: (1) ANXA1<sup>-/-</sup> mice fed a HFD have a more severe diabetic phenotype (e.g. more severe dyslipidemia, insulin resistance, hepatosteatosis and proteinuria) compared to WT mice fed a HFD; (2) treatment of WT-mice fed a HFD with hrANXA1 attenuated the development of insulin resistance, hepatosteatosis and proteinuria. We demonstrate here for the first time that ANXA1<sup>-/-</sup> mice have constitutively activated RhoA. Interestingly, diabetic mice, which have reduced tissue expression of ANXA1, also have activated RhoA. Treatment of HFD-mice with hrANXA1 restored tissue levels of ANXA1 and inhibited RhoA activity, which, in turn, resulted in restoration of the activities of Akt, GSK-3 $\beta$  and eNOS secondary to re-sensitization of IRS-1 signaling. We further demonstrate in human hepatocytes that ANXA1 protects against excessive mitochondrial proton leak by activating FPR2 under hyperglycaemic conditions. In summary, our data suggest that a) ANXA1 is a key regulator of RhoA activity, which restores IRS-1 signal transduction and b) recombinant human ANXA1 may represent a novel candidate for the treatment of T2D and/or its complications.

**Keywords:** Type-2 diabetes, metabolism, Annexin A1, nephropathy, hepatosteatosis, Rho A,

## Introduction

Obesity and metabolic syndrome are of global health concern and are an independent risk factor of diseases characterized by systemic inflammation such as type-2 diabetes mellitus (T2D), non-alcoholic fatty liver disease (NAFLD/NASH)(1), chronic kidney disease (CKD) (2) and cardiovascular disease (3). Even with aggressive strategies to modulate both plasma lipid profiles and blood glucose levels, microvascular complications develop over time in patients with T2D (4). Indeed, approximately 30% of patients with T2D develop diabetic nephropathy, which is the leading cause of end-stage renal disease (ESRD). Peripheral insulin resistance drives a vicious pathophysiological cycle leading to T2D, ectopic adiposity and chronic inflammation, coupled with a down-regulation of pro-survival/anti-inflammatory pathways. Identifying endogenous molecules that are both anti-inflammatory and tissue protective agents will lead to the discovery of novel drug target for the treatment of diabetes.

Annexin A1 (ANXA1) is an endogenous anti-inflammatory protein, principally known as a regulator of peripheral leukocyte migration and a promoter of macrophage phagocytosis of apoptotic neutrophils (5). ANXA1 is expressed by endothelial cells, tubular epithelial cells, adipocytes and low levels of ANXA1 can be detected in the circulation under physiological conditions. We recently demonstrated that the plasma levels of ANXA1 are elevated in patients with type-1 diabetes (6) and multiple sclerosis (7). Cristante *et al.* (7) demonstrated a mechanistic link between RhoA and ANXA1, whereby ANXA1 interacts with RhoA to alter actin-polymerization and maintain blood brain barrier integrity. RhoA has far reaching implications in many diseases including type-2 diabetes, its activity is upregulated by oxidative stress and hyperglycemia. Many strategies, which inhibit the Rac/RhoA pathway, also reduce microvascular complications in diabetes via a reduction in inflammation and fibrosis (8)(9).

In the present study, we use a translational approach to gain a better insight into the role of ANXA1 in a) patients with T2D and b) a murine model of high fat diet (HFD) induced insulin resistance. Moreover, we investigated the effect of human recombinant ANXA1 (hrANXA1) as a potential treatment for experimental T2D and its microvascular complications.

## Methods

### Human studies and subjects and ethic statement

Human volunteers and patients were recruited within the general population enrolled in the PLIC study (*Progressione delle Lesioni Intimali Carotidee*) at the Center for the Study of Atherosclerosis, SISA Bassini Hospital Cinisello B. Italy (Ethical approval SEFAP/Pr0003F University of Milan 06/2/2001) (10). Patients with T2D were identified from their clinical history, outpatient's registries and/or hospital archives, following international guidelines (11). Subjects included in the study were defined as "normoglycemic" if the following criteria were met: No self-reported T2D, patients are not being treated with glucose lowering drugs and fasting glucose levels are below 110 mg/dL (at least 3 previous controls). All patients and healthy volunteers gave written informed consent in adherence to the Declaration of Helsinki. Clinical data was collected, and biochemical analyses were performed as previously described (12). Urinary albumin levels were determined by immunoturbidimetry on fresh samples of the morning. Fatty Liver Index was calculated from BMI, waist circumference, gamma-glutamyl-transpeptidase (GGT) and triglyceride levels in fasting condition as previously described (13).

Healthy subjects" from the PLIC cohort were only included if they had no evidence of hepatic steatosis (ultrasound determined, not shown), renal damage or type-2 diabetes (T2D). Clinical information [clinical and pharmacological history, Body Mass Index (BMI) and waist-hip ratio (waist)] was collected during the outpatient activity, which was part of the study design of PLIC. Biochemical, lipid profile (LDL-C "LDL cholesterol levels"), liver enzymes (including gamma-glutamyl-transferase), C-reactive protein (CRP) and glucose level were determined as previously described (12). Briefly, blood samples were drawn after overnight fasting (ten hours at least) from antecubital vein and collected in EDTA tubes (BD Vacuette®). Blood samples were then centrifuged at 3'000 rpm for 12 minutes in order to separate plasma for glucose quantification. Determination was performed by enzymatic method (hexokinase reaction) through automatic sample analyzer (RX Daytona, Randox Laboratories Ltd®, Crumlin, UK).

*Fatty liver Index (FLI) was determined as previously described, according to the following formula:  $FLI = (e^{0.953 \cdot \log(\text{triglycerides})} + 0.139 \cdot BMI + 0.718 \cdot \log(GGT) + 0.053 \cdot \text{waist}$*

circumference – 15.745) / (1 + e<sup>0.953\*log<sub>e</sub>(triglycerides) + 0.139\*BMI + 0.718\*log<sub>e</sub>(GGT) + 0.053\*waist circumference – 15.745) \* 100.</sup>

Chronic kidney disease (CKD) and its stages (CKD3, CKD4, and CKD5) were determined following determination of glomerular filtration rate (GFR), according to validated international criteria. When compared to healthy controls, CKD patients had a GFR of less than 60 ml/min/1.73 m<sup>2</sup> associated with albuminuria (urinary albumin over 30 mg/g of total urinary proteins).

### **Use of experimental animals-ethics statement**

The experimental protocols used in this study have been approved by the Animal Welfare Ethics Review Board (AWERB) of Queen Mary University of London and the University of Turin, the study was performed under license issued by the home office (Procedure Project License; PPL: 70/8052) and committees (DGSAF 0021573-P-12/11/2013 and DGSAF). Animal care was in accordance with the Home Office guidance on Operation of Animals (Scientific Procedures Act 1986) published by Her Majesty's Stationery Office and the Guide for the Care and Use of Laboratory Animals of the National Research Council and are in keeping with the European Directive (2010/63/EU) as well as the Guide for the Care and Use of Laboratory Animals.

### **Animals and experimental procedures**

This study was carried out on 10 weeks old ANXA1<sup>-/-</sup> mice on a C57BL/6 background (14) and wild-type (WT) C57BL/6 mice, housed in the same unit under conventional housing conditions at 25±2 °C. WT and ANXA1<sup>-/-</sup> mice were randomly assigned either normal diet (chow) or high fat, high sugar diet (HFD) (D12331 diet, Research Diet Inc., USA). All mice had access to food and water *ad libitum*. After 4 weeks of dietary manipulation, mice were randomly assigned to a treatment group receiving either with hrANXA1 (40µg/kg, i.p.) or vehicle (Hepes 50mM, NaCl 140 mM i.p.) 5 days per week for 6 weeks. Mice were harvested the morning after receiving the last dose of hrANXA1 (day 5 of week 6 of treatment). hrANXA1 was produced and purified as previously published, approximately 0.5% of injected dose per gram (ID/g) ANXA1 remained in the circulation 24 hours post injection as previously reported (15).

### **ELISA for ANXA1**

A homemade sandwich ELISA was used to measure plasma ANXA1 (16). Briefly, ELISA-treated plates (Nunc MaxiSorp, ThermoScientific, UK) were incubated overnight with capture antibody 20µg/ml (mouse monoclonal antibody, generated in house) in bicarbonate buffer (25 mM NaHCO<sub>3</sub>, 25 mM Na<sub>2</sub>CO<sub>3</sub>, pH 9.6). The plate was then washed 3 times with bicarbonate buffer and blocked in blocking buffer (0.1 % BSA, PBS) for 1 h at 37 °C. Then 100 µl of sample and standard in assay diluent (Tween-20 0.05 % (v/v), PBS) were loaded and incubated for 1 h at 37 °C, then washed 5 times with wash buffer (0.9% (w/v) NaCl, 0.05 % (v/v) Tween-20, dH<sub>2</sub>O). Following this wells were incubated with 1µg/ml of detecting antibody (rabbit polyclonal anti-ANXA1; Invitrogen, UK) for 1 h at 37 °C. After 5 washes, immuno-complexes were detected by adding the goat-anti-rabbit IgG with conjugated alkaline phosphatase for 30 min. After 5 washes, the substrate, p-nitrophenyl phosphate (Sigma Aldrich, UK) was added and left for 30 min for full development of color. The plate was then read absorbance at 405 nm and corrected at 540 nm as a reference wavelength, using a spectofluorometer (Tecan Infinite M200 Pro, Tecan, Austria).

### **Oral glucose tolerance test (OGTT)**

Mice were fasted for 6 h prior to testing, then given an oral bolus of glucose (2g/kg in H<sub>2</sub>O p.o.). Blood glucose was measured from the tail vein at time 0 and then at 15 min intervals for 120 min using glucometer (Accu-Chek Compact System, Roche Diagnostics); basal non fasted blood glucose

### **Blood and biochemical analysis**

Serum triglyceride and total cholesterol were measured by standard enzymatic assay using reagent kits (Hospitex Diagnostics, Italy). Liver triglycerides were measured via a colorimetric assay (Abnova Corporation, Germany). ALT and urine and serum creatinine were measured by a commercial veterinary testing laboratory (IDEXX, Wetherby, UK); serum insulin and urine albumin were measured using commercially available ELISA kits (Abcam, Cambridge, UK, and Bethyl Laboratories, Montgomery, TX, USA).

### **Histological analysis**

*Oil Red – O:* Frozen liver samples were embedded in OCT, and cut in 10 µm sections. Section were brought to room temperature, fixed with 10 % buffer formalin for 5 min, washed with 60 % isopropanol, then saturated with Oil Red O (1% w/v, 60 % isopropanol) for 15 min, washed in 60 % isopropanol and rinsed in distilled water. The sections were then mounted in aqueous mounting medium with coverslips. Images were acquired using a NanoZoomer Digital Pathology Scanner (Hamamatsu Photonics K.K., Japan) and analyzed using the NDP Viewer software. Additionally 10 randomly selected fields of view from each liver section were used to assess lipid accumulation.

*Periodic Acid Schiff's:* Kidney samples were obtained at the end of the experiment and fixed in 10 % neutral-buffered formalin for 48 h and histology staining was performed. Briefly, kidney tissue was embedding in paraffin and processed to obtain 4 µm sections. After deparaffinization and sections were rehydrated through graded alcohol to distilled water. The sections were then incubated with saturated in Periodic Acid Schiff's (Sigma, UK) solution for 30 min and washed in distilled water. Then sections were then dehydrated through graded alcohols and cleared before mounting with coverslips. Images were acquired using a NanoZoomer Digital Pathology Scanner (Hamamatsu Photonics K.K., Japan) and analyzed using the NDP Viewer software. Additionally 10 randomly selected fields of view from each kidney section were used to assess structural alteration of the proximal convoluted tubules and general renal histopathology.

### **Western Blot analysis**

Semi-quantitative **western blot analyses** of phosphorylated and/or total form of IRS-1, Akt, GSK-3β, eNOS, ANXA1, RhoA and MYPT1 were carried out in tissue samples as described before (6). Briefly, liver, skeletal muscle and kidney samples were homogenized in protein homogenization buffer and centrifuged at 1300g for 5 min at 4°C. To obtain the cytosolic protein fraction, supernatants were centrifuged at 16000g at 4°C for 40 min. Protein content was determined on cytosolic extracts using bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific, Rockford, IL). Proteins were separated by 8% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidenedifluoride (PVDF) membrane, which were blocked with a solution of 5% dry milk in TBS-Tween for 2h. **Membranes were incubated with a primary antibody (1:1000 rabbit anti-total IRS-1;**

1:1000 rabbit anti-pSer<sup>307</sup> IRS-1; 1:1000 rabbit anti-total Akt; 1:1000 rabbit anti-pSer<sup>473</sup> Akt; 1:1000 rabbit anti-total GSK-3 $\beta$ ; 1:1000 rabbit anti-pSer<sup>9</sup>GSK-3 $\beta$ ; 1:200 rabbit anti-ANXA1; 1:1000 rabbit anti-total RhoA; 1:1000 rabbit anti-pSer<sup>188</sup> RhoA; 1:1000 rabbit anti-total MYPT1 and 1:1000 rabbit anti-pSer<sup>853</sup> MYPT1). Membranes were incubated with a secondary antibody conjugated with horseradish peroxidase (1:2000) for 30 min at room temperature and developed with ECL detection system. The immunoreactive bands were visualized by autoradiography and the densitometry analysis was performed using Gel Pro Analyser 4.5, 2000 software (Media Cybernetics, Silver Spring, MD, USA). The membranes were stripped and incubated with alpha tubulin monoclonal antibody (1:5000) and subsequently with an anti-mouse antibody (1:2000) to assess gel-loading homogeneity. Densitometry analysis of the related bands is expressed as relative optical density, and normalized using the related WT + vehicle or sham band.

### Oxygen consumption rate

HepG2 cells ( $3 \times 10^5$ ) were seeded in 96-well Seahorse plates in serum free medium containing 5.5 mM glucose, 25 mM glucose, 25 mM glucose + hrANXA1 (20  $\mu$ g/mL) or 25 mM glucose + hrANXA1 (20  $\mu$ g/mL) + WRW4 an FPR2 antagonist [0.9 mM- Tocris- inhibits WKYMVm binding to FPR2 ( $IC_{50} = 0.23 \mu$ M)] and incubated for 48 h. to measure OCR, the medium was replaced with XF Mitoassay medium (pH 7.4) and incubated without CO<sub>2</sub> for 30 min. Then, basal OCR was measured and wells were sequentially injected with: 1) oligomycin (1.0  $\mu$ M), an ATP synthase blocker; 2) carbonyl cyanide p-[trifluoromethoxy]-phenyl-hydrazine (FCCP) (0.5  $\mu$ M), a proton ionophore; and 3) a mix of rotenone (0.5  $\mu$ M) and antimycin A (0.5  $\mu$ M), inhibitors of electron transport. OCR was measured three times following each injection with an interval of 6 minutes between each reading. Experiments were performed three times in triplicate and all values of OCR were normalized to protein content of individual wells. Data was gathered on SeaHorse XFe96 Analyzer (Agilent Technologies) and data analyzed using Wave Software (Agilent Technologies).

### Image Stream

HepG2 cells were seeded into 6-well plates at a density of  $1 \times 10^6$  and then treated with DMEM containing glucose (5.5 mM or 25 mM). After 48 h, cells were harvested and



fixed in paraformaldehyde (2 %) for 10 min at room temperature and washed in PBS. Cells were then blocked in blocking solution (PBS + 0.2 % BSA) for 30 min at room temperature. To perform the staining of FPR2 on the membrane, cells were then incubated with primary anti-body [rabbit anti-FPR2 (1:50)] (Acris Antibodies) (30 min at room temperature), followed by incubation with secondary anti-body [anti-rabbit AF488 (1:100)] (30 min at room temperature). From intracellular FPR2 and ANXA1 cells were permeabilized with permeabilization solution (PBS + Tween20 0.5 % v/v, 10 min at room temperature); cells were then washed and blocked in blocking solution (PBS + 0.2 % BSA, 30 min at room temperature). Cells were then incubated with primary anti-body [rabbit anti-FPR2 (1:50)] (Acris Antibodies) and mouse anti-ANXA1 (Invitrogen (1:100)) washed and incubated with secondary anti-body (anti-rabbit AF647 (1:100) and anti-mouse AF405 (1:100)) (30 min at room temperature), and then washed. Imaging flow cytometry was performed on an ImageStreamx Mark II operated by INSPIRE software (Amnis Corporation). A sample of HEPG2 that were not incubated with antibodies were collected at the same settings, in order to gate different cell populations (negative or positive staining). In each experiment, a template of settings was created and it was applied to all files. A total of 10,000 events were collected for each sample, and data were analyzed using IDEAS Application 6.1 software (Amnis Corporation).

### **Human Phospho-kinase Array**

HepG2 cells were incubated in DMEM containing 5.5 mM glucose, 25 mM glucose, 25 mM glucose + hrANXA1 (20 $\mu$ g/mL) or 25 mM glucose + hrANXA1 (20 $\mu$ g/mL)+ WRW4 (0.9 mM) and incubated for 48 h. Cells were washed in PBS containing protease inhibitors and cell lysates extracted as per manufactures instructions. Protein concentration was quantified and 600  $\mu$ g of protein was used per membrane of a Proteome Profiler, Human Phospho-kinase Array (R&D Systems). After visualization of the spots, the signals were measured using Image Studio LICOR, normalization was carried as per manufacturers instruction and changes plotted in a heat map expressed as fold change to 5.5 mM glucose for each individual phosphorylation site using PRISM.

### **Statistical analysis**

All data in the text and figures are presented as mean  $\pm$  standard error mean (SEM) of

n observations, where n represents the number patients per group (Figure 1/2), animals studied (Figures 3-7) or technical replicates (Figure 8). All statistical analysis was calculated using GraphPad Prism 7 for Mac (GraphPad Software, San Diego, California, USA). Data without repeated measurements was assessed by a one-way ANOVA followed by Bonferroni correction. Some of the human data were analyzed by Student's t-test (data with normal distribution) or Mann Whitney U test (data that were not normally distributed). Correlation studies were analyzed by linear regression using Fishers F test. In all cases a  $p < 0.05$  was deemed significant.

## Results

### 1. *Patients with type-2 diabetes have elevated plasma levels of ANXA1 correlated with increased dyslipidemia and fatty liver index.*

To gain a better understanding of the role of ANXA1 in man, we compared the plasma levels of ANXA1 in gender- and age-matched subjects with normoglycemia or T2D (Table 1). Of note, patients with T2D had significantly higher circulating plasma levels of ANXA1 (Figure 1A) when compared with normoglycemic subjects. Moreover, the plasma levels of ANXA1 in patients with T2D correlated positively with fatty liver index, a surrogate marker of hepatic lipid accumulation (Figure 1B), and serum LDL-C and total cholesterol (Figure 1C and D), thus implying a relation between elevated circulating ANXA1 levels and a complex metabolic pattern, including altered glucose control, hepatic steatosis and dyslipidemia. As expected, C-reactive protein (CRP) (a marker of chronic low-grade inflammation) correlated positively with increased BMI in our cohort of patients with T2D (Figure 2A). Interestingly circulating plasma ANXA1 did not correlate with either BMI or CRP (Figure 2B and C). Additionally, we observed no correlation of CRP and lipid levels (Figure 2D and E). Additionally, ANXA1 levels were not further elevated in patients who presented with diabetes and CKD (Figure 2F). This result is particularly interesting, as a heightened level of systemic inflammation is classically seen in patients with CKD. Taken collectively, these observations suggest that the observed increase in plasma ANXA1 is not a consequence of increased systemic inflammation, but secondary to the altered metabolic state and aberrant lipid handling.

### 2. *ANXA1 attenuates the development of obesity and insulin resistance in HFD fed mice.*

To gain a better understanding of the role of ANXA1 in the pathophysiology of T2D, we used a murine model of HFD-induced insulin resistance, hepatic steatosis and renal dysfunction (diabetic nephropathy). Consistent with the observation in patients with T2D, mice fed a HFD had elevated levels of circulating ANXA1 (Figure 3A). We also show that the ANXA1 protein levels were dramatically reduced in key target tissues (liver, kidney and skeletal muscle) of animals fed a HFD (Figure 3B) compared to chow fed mice.

When compared to chow-fed mice, WT-mice fed a HFD gained more weight (Table 2), had elevated levels of serum insulin, higher (non-fasted) blood glucose levels and a significant impairment in tolerance to oral glucose challenge (oral glucose tolerance test, OGTT) (Figure 2C-G). ANXA1<sup>-/-</sup> fed a HFD gained significantly more weight (Table 2), had higher blood glucose levels (Figure 3D) and an even more severely impaired OGTT (Figure 3F/G) when compared to HFD-fed WT-mice. HFD-fed WT-mice treated with hrANXA1 had normal tissue levels of ANXA1 (Figure 3B), lower serum insulin levels, lower (non-fasted) blood glucose levels (Figure 3C/D) and an improved OGTT (Figure 3E/G) when compared to HFD-fed WT-mice. Administration hrANXA1 to ANXA1<sup>-/-</sup> mice (rescue experiment) resulted in significantly lower serum insulin levels, blood glucose levels, a reduction in weight gain and an improvement in OGTT; suggesting that endogenous ANXA1 is a key mediator of glucose homeostasis.

3. *ANXA1 improves IRS-1 signal transduction in HFD-induced insulin resistance.*  
As endogenous ANXA1 protected against the development experimental diabetes and treatment with hrANXA1 improved the diabetic phenotype of HFD-fed mice, we next investigated the potential mechanisms underlying the observed beneficial effects of both hrANXA1 and endogenous ANXA1.

When compared to WT-mice fed a chow diet, WT-mice fed a HFD exhibited an increase in the degree of phosphorylation of insulin substrate receptor-1 (IRS-1) on Ser<sup>307</sup> in skeletal muscle (Figure 4A) and liver (Figure 4D); as well as a decrease in the phosphorylation of downstream effectors of the insulin signaling pathway, protein kinase B (Akt) on Ser<sup>473</sup> (Figure 3B/E) and glycogen synthase kinase-3 $\beta$  (GSK-3 $\beta$ ) on Ser<sup>9</sup> in both skeletal muscle and liver (Figure 4C/F). All of the above findings suggest that WT-mice fed a HFD had developed peripheral insulin resistance. ANXA1<sup>-/-</sup> mice fed a HFD exhibited a further significant increase in the degree of phosphorylation of IRS-1 on Ser<sup>307</sup> in both skeletal muscle and liver (Figure 4A/D); resulting in a decrease in the phosphorylation of Akt on Ser<sup>473</sup> (Figure 4B/E) and glycogen synthase kinase-3 $\beta$  (GSK-3 $\beta$ ) on Ser<sup>9</sup> (Figure 4C/F). These data are consistent with the more severe diabetic phenotype observed in ANXA1<sup>-/-</sup> mice fed a HFD.

Treatment of WT-mice fed a HFD with hrANXA1 attenuated the increase in phosphorylation of IRS-1 on Ser<sup>307</sup>, and the subsequent decrease in phosphorylation of

Akt on Ser<sup>473</sup> and GSK-3 $\beta$  on Ser<sup>9</sup> in both skeletal muscle (Figure 4A-C) and liver (Figure 4D-F). Additionally, when hrANXA1 was given to ANXA1<sup>-/-</sup> mice (rescue experiment), all abnormal signaling events were restored to that of WT mice fed a chow diet and highlighting of ANXA1 as a signaling molecule in the IRS-1 signal transduction pathway.

#### 4. *ANXA1 attenuates dyslipidemia, steatosis, liver injury and renal dysfunction in HFD fed mice.*

In addition to developing insulin resistance, WT-mice fed a HFD had increased levels of serum triglycerides, cholesterol, a 10-fold increase in liver triglyceride levels (Figure 5A-C) **associated** with an increase in Oil Red-O staining in the liver (Figure 5G), suggesting the development of dyslipidemia and liver steatosis. Lipid deposition and steatosis in the liver is associated with liver injury; WT-mice fed a HFD had elevated serum ALT levels (Figure 5D) compared to WT mice fed a chow diet. ANXA1<sup>-/-</sup> mice fed a HFD had **even** significantly higher serum triglyceride levels, **further** increased Oil Red-O staining in **the** liver and **even higher** ALT levels **when** compared to WT mice fed a HFD (Figure 5A-D, G). In contrast, WT-mice fed a HFD and treated with hrANXA1 had significantly lower serum cholesterol and liver triglyceride levels, less Oil Red-O staining in the liver and significantly lower ALT levels (Figure 5A-D, G) compared to HFD-fed WT-mice. Treatment of ANXA1<sup>-/-</sup> mice with hrANXA1 (rescue experiment) resulted in a reduction in liver triglyceride levels, serum ALT and Oil Red-O accumulation in the liver compared to ANXA1<sup>-/-</sup> mice fed a HFD (Figure 5A-D, G). Taken together, these findings suggest that ANXA1 protects against the development of dyslipidemia and liver steatosis/injury.

T2D ultimately drives the development of microvascular complications including diabetic nephropathy. WT-mice fed a HFD exhibited an elevated albumin-to-creatinine ratio (ACR) and decreased creatinine clearance (Figure 5E/F) compared to chow-fed WT-mice, suggesting the development of proteinuria (a marker of diabetic nephropathy) and renal dysfunction. The development of proteinuria was associated with significant morphological changes. WT-mice fed a HFD have more vacuolar degeneration at the level of the S1-S2 segment of the proximal convoluted tubules, while other tubular structures of the nephron remained histologically preserved (Figure 5H). There was also a marked loss of brush boards in the S1-S2 segment of the

proximal convoluted tubules (yellow arrows). All histological markers of tubular degeneration were more marked in the kidneys from ANXA1<sup>-/-</sup> mice fed on a HFD (Figure 4H). Which correlated with ANXA1<sup>-/-</sup> mice fed a HFD having further elevation in ACR, (Figure 5E) suggesting the development of more severe proteinuria. In contrast, administration of hrANXA1 to HFD-fed WT-mice attenuated the rise in ACR and the decrease creatinine clearance (Figure 5E/F) and preserved the kidney from signs of tubular degeneration (Figure 5H).

#### 5. *ANXA1 regulates eNOS and RhoA activation in a model of HFD-induced insulin resistance*

One of the key drivers of proteinuria and, indeed, renal dysfunction is renal hypertension, which is, in part driven by the development of endothelial dysfunction. WT-mice fed a HFD **had** a significant reduction in the phosphorylation of eNOS on Ser<sup>1177</sup> in the kidney (Figure 6) compared to chow-fed WT animals; while hrANXA1 treatment significantly prevented the reduction in phosphorylation of eNOS on Ser<sup>1177</sup> (Figure 6). Moreover, ANXA1<sup>-/-</sup> mice fed a HFD also demonstrated significantly reduced phosphorylation of eNOS on Ser<sup>1177</sup>. Interestingly, ANXA1<sup>-/-</sup> mice fed with HFD and treated with hrANXA1 (rescue experiment) **had no changes** in the phosphorylation of eNOS on Ser<sup>1177</sup> (Figure 6), **indicating that hrANXA1 prevents the decline in eNOS phosphorylation seen in ANXA1<sup>-/-</sup> mice fed with HFD.**

Having shown that endogenous ANXA1 limits, and **that** administration of hrANXA1 attenuates the development of peripheral insulin resistance as well as liver injury and kidney dysfunction caused by a HFD, we further **explored** the potential mechanism(s) underlying the observed beneficial effects of ANXA1. Activation of RhoA plays a key role in the development of both peripheral insulin resistance and in the development of microvascular complications of diabetes(17). We have previously demonstrated that ANXA1 interacts with RhoA(7). Here we demonstrate that the tissue levels of ANXA1 are decreased in mice fed a HFD (Figure 2B). This resulted in reduced phosphorylation of RhoA on Ser<sup>188</sup> (increased GTPase activity) and in an increase in the phosphorylation of downstream effector MYPT1 on Thr<sup>853</sup> in the kidney (Figure 7A/D), liver (Figure 6B/E) and skeletal muscle (Figure 7C/F), when compared to chow-fed WT-mice. **Interestingly**, ANXA1<sup>-/-</sup> mice also have a reduced phosphorylation of RhoA on Ser<sup>188</sup> (Figure 7A-C), and **an** increased phosphorylation of MYPT1 on Thr<sup>853</sup> (Figure 7D-F)

(regardless of dietary manipulation) in kidney and skeletal muscle, suggesting that ANXA1<sup>-/-</sup> mice have constitutively activated RhoA-GTPase. Treatment of ANXA1<sup>-/-</sup> mice fed a HFD with hrANXA1 (rescue experiment) resulted in an increase in the degree of phosphorylation of RhoA on Ser<sup>188</sup> (Figure 7A-C) and attenuation of the degree of phosphorylation on MYTP1 on Thr<sup>853</sup> (Figure 7D-F), in liver, kidney and skeletal muscle; demonstrating conclusively that ANXA1 regulates RhoA activity.

From a therapeutic point of view, treatment of WT HFD-fed mice with hrANXA1, also restored the tissue levels of ANXA1 in liver, kidney and skeletal muscle (Figure 2B). This prevented the reduction of the phosphorylation of RhoA on Ser<sup>188</sup> (Figure 7A-C), and the associated increase in phosphorylation of MYPT1 on Thr<sup>853</sup> (Figure 7D-F) observed in HFD-fed WT-mice. These findings support the view that ANXA1 regulates the activity of RhoA in experimental diabetes, which, in turn, limits the development of peripheral insulin resistance and protects the kidney and liver from functional decline.

6. *ANXA1 protects against excessive proton leak via FPR2 in human hepatocytes.* One of the major sites of both lipid and glucose handling is the liver. Therefore, we wanted to investigate whether ANXA1 is involved in the regulation of energy homeostasis in human hepatocytes. Therefore, in order to evaluate whether hepatic mitochondrial respiration was altered under high glucose conditions, oxygen consumption rate (OCR) was measured (Figure 8A). HEPG2 cells grown in high glucose medium had higher basal OCR (Figure 8B), increased ATP-linked OCR (Figure 8C) leading to excessive proton leak (Figure 8D), which can lead to the formation of reactive oxygen species and cellular damage. When HEPG2 cells were incubated in high glucose (25 mM) medium in the presence of hrANXA1, hrANXA1 attenuated the increases in basal OCR (Figure 8B), ATP-linked OCR (Figure 8C), and proton leakage (Figure 7D). We hypothesized that the observed beneficial effects of treatment with hrANXA1 are mediated through the FPR2 receptor. Interestingly, expression levels of FPR2 was not altered by exposure of HEPG2 cells to high glucose (25 mM) medium, whereas ANXA1 levels were decreased (figure 8E). Using a specific FPR2 antagonist, we were able to block the effects of hrANXA1 on basal OCR (Figure 8B), ATP-linked OCR (Figure 8C) and proton leak (Figure 8D) suggesting the

beneficial effects of hrANXA1 in reducing excessive proton leak are, indeed, FPR2 mediated.

7. *Effects of hrANXA1 on MAPK and Akt pathway are FPR2 mediated in human hepatocytes*

To get a better understanding of the signaling pathways modulated by hrANXA1 in HepG2 cells during exposure to high glucose, the phosphorylation states of 43 potentially relevant pathways were measured using a human phospho-kinase proteome profiler array (Figure 8F and Supplemental figure 1). Our results demonstrate that HepG2 cells grown in high glucose medium (25 mM) had an increase in phosphorylation of key members of the MAPK pathway (p38, JNK, ERk1/2 and RSK1/2) and in the Akt pathway (Akt, GSK-3B, p70 and PRAS40), while key members of the pro-inflammatory JAK/STAT pathway exhibited decreased inhibitory phosphorylation (Stat2 and Stat5a). When HepG2 cells were grown in high glucose medium and treated with hrANXA1, the observed increases seen in the phosphorylation of the MAPK (p38, JNK, ERk1/2 and RSK1/2) and the Akt pathway (GSK-3B, p70 and PRAS40) were attenuated. Additionally, AMPKa2 phosphorylation was further increased in the presence of hrANXA1. Pre-incubation with an FPR2 antagonist abolished all of the above effects of treatment with hrANXA1, strongly suggested that ANXA1 is signaling through FPR2 (Figure 8F).



## Discussion

The key findings of our study are that patients with T2D have elevated plasma ANXA1 levels, which correlate positively with fatty liver index and serum lipid levels, but not with markers of systemic inflammation, suggesting that the ANXA1 levels in patients with T2D are not regulated by systemic inflammation, but are a consequence of aberrant lipid handling. To elucidate the role of ANXA1 in the pathophysiology of obesity/metabolic syndrome, we used a model of HFD-induced insulin resistance in WT and ANXA1<sup>-/-</sup> mice. Consistent with our patient data, mice fed a HFD showed elevated serum ANXA1 levels, while their tissue levels were reduced (see below). ANXA1<sup>-/-</sup> mice fed a HFD developed a more severe diabetic phenotype (compared to WT mice) as indicated by higher fasting glucose levels, increased impairment in the oral glucose tolerance test and increased impairment of insulin signaling (IRS-1, Akt and GSK-3 $\beta$ ). Additionally, treatment of WT-mice fed a HFD with hrANXA1 reduced the diabetic phenotype, restored IRS-1 and Akt (liver and skeletal muscle) and eNOS (kidney) activity. ANXA1<sup>-/-</sup> mice fed on a HFD also developed severe dyslipidemia, hepatosteatosis (lipid accumulation in the liver) and renal dysfunction (proteinuria), while the therapeutic administration of hrANXA1 attenuated both hepatosteatosis and the renal dysfunction/proteinuria caused by HFD. HFD-fed mice had lower intracellular levels of ANXA1 in the kidney, liver and skeletal muscle resulting in the activation of small GTPase RhoA and of the downstream effector MYTP1: This key finding was confirmed in ANXA1<sup>-/-</sup> mice, which had constitutively activative RhoA. Treatment with hrANXA1 restored intracellular ANXA1 levels, reduced RhoA activation and restored IRS-1 signaling. Thus, we demonstrate here for the first time a mechanistic link between ANXA1 levels, RhoA activity and IRS-1 signaling. Treatment of human hepatocytes with hrANXA1 also reduced the mitochondrial proton leak in an FPR2-dependent manner. All of the above findings support the conclusions that endogenous ANXA1 prevents the development of insulin-resistance and associated microvascular complications, while pharmacologically administered hrANXA1 attenuates the development of metabolic and secondary microvascular complications in experimental T2D.

What, then, is the mechanism(s) by which ANXA1 attenuates insulin resistance in experimental T2D and protects against the development of secondary complications?

The observed impairment in glucose tolerance seen in mice fed on a HFD is, in part, mediated by alterations in insulin signaling in liver and skeletal muscle. The IRS-1/Akt/GSK-3 $\beta$  signaling cascade is a key regulator of glucose transportation, glycogen synthesis and energy metabolism (glycolysis)(18). Peripheral insulin resistance is attributed to an increase in the phosphorylation of Ser<sup>307</sup> on IRS-1; this uncouples IRS-1 from the insulin receptor blunting the ability of insulin to signal through its receptor, which, in turn, reduces GLUT4 translocation to the cell surface to facilitate glucose uptake in peripheral organs, leading to hyperglycemia (19). Mice fed a HFD showed increased phosphorylation of Ser<sup>307</sup> on IRS-1 (in the liver/skeletal muscle), which was further augmented in ANXA1<sup>-/-</sup> mice. In contrast, treatment with hrANXA1 attenuates this increase in the phosphorylation of Ser<sup>307</sup> on IRS-1 resulting restoration/maintenance of normal glucose levels in the blood (20).

Many of the beneficial effects of anti-diabetic drugs are mediated through inhibition of the GTPase RhoA. Metformin reduces RhoA activity and activates AMPK (21), (22), while Fasudil, a selective RhoA inhibitor used to treat diabetic nephropathy, improves insulin signaling and nephropathy by correcting glucose and lipid homeostasis in obese Zucker rats (23),(24),(25). Statins, which are best known for their lipid-lowering effects, also ameliorate the progression of diabetic nephropathy, and both effects have been attributed to inhibition of RhoA/ROCK (26),(27),(28),(29),(30). Interestingly, RhoA activation **is** inhibited by ANXA1 (7), suggesting an original mechanistic link between ANXA1 **levels, RhoA activation** and the development of insulin resistance. We demonstrate that mice fed a high fat diet have an increase in the circulating levels of ANXA1, but this was associated with reduced expression in skeletal muscle, liver, kidney, which (in turn) resulted in activation of RhoA. However, we do not know **whether** the circulating ANXA1 **measured in animals and man** is inactive or **whether** the subsequent treatment restores the loss of the biological activity; **though we need to take in consideration the limited comparability of the mouse model vs the human condition**. Moreover we **also** demonstrate that ANXA1<sup>-/-</sup> mice have constitutively activated RhoA **activity** suggesting that ANXA1 is a regulator of RhoA activity. Thus, we propose that endogenous ANXA1 is a regulator of RhoA/ROCK activity under physiological conditions. Indeed, treatment of HFD-fed mice with hrANXA1 restored intracellular ANXA1 levels/signaling (Figure 2B), modulated RhoA phosphorylation and re-stabilized the insulin receptor (**resulting** in reduced phosphorylation of IRS-1)

allowing restoration of insulin signaling and glucose homeostasis. Cristante et al. (7) have previously demonstrated in the brain **microvascular** endothelium that ANXA1 and RhoA co-precipitate together suggesting a direct molecular interaction. Here we demonstrate for first time a mechanistic link between ANXA1, RhoA and IRS-1 signaling *in vivo*.

Impairments in insulin sensitivity are associated with excessive lipid deposition (19). WT mice fed on a HFD developed dyslipidemia, had excessive fat accumulation in their peripheral fat beds (Table 1) and in the liver causing hepatic steatosis **and liver injury (elevated ALT levels)**, all of which **were** more severe in ANXA1<sup>-/-</sup> mice. In contrast, mice fed a HFD and treated with hrANXA1 show reduced adiposity, and a reduction in lipid and triglyceride accumulation in the liver. Collectively, our findings suggest that ANXA1 reduces the development of hepatic steatosis and the associated liver injury by inhibition of RhoA activity and restoration of IRS-1 signaling. Indeed, our human data shed further light on the role of ANXA1 in lipid homeostasis, **as ANXA1 plasma levels correlate positively** with increased lipids in both the liver and the circulation, **but do not correlate** with systemic inflammation, suggesting a new biological function of ANXA1 beyond those of as an anti-inflammatory mediator.

We also report here that mice fed a HFD have reduced phosphorylation (Ser<sup>473</sup>) and, hence, reduced activation of Akt. Activated Akt regulates inflammatory and pro-survival responses (31). We also show in human hepatocytes that treatment with ANXA1 re-activated Akt **in an FPR2-dependent manner**. One consequence of inhibition of Akt is that organs are less resistant to stressor stimuli including hyperglycemia and/or hyperlipidemia and subsequently develop organ injury (15). In contrast, **restoration of the degree of** activation of the Akt **pathway** reduces organ injury in many conditions associated with inflammation including sepsis-induced organ dysfunction (32),(33), hemorrhagic shock-induced organ dysfunction (34),(35), and diabetes (6)(19). The N-terminal peptide of ANXA1 (Ac2-16) **also** reduces tissue injury by activating Akt in experimental models of cardiac/renal reperfusion injury(36),(37) and non-alcoholic steatohepatitis (38). Activation of Akt also results in inhibition GSK-3 $\beta$  (Ser<sup>9</sup> phosphorylation) resulting in activation of glycogen synthase, which converts glucose to glycogen for storage in the liver. Here we demonstrate that mice fed on a HFD have decreased activation of GSK-3 $\beta$ , which could result in a reduction in

glycogen synthesis and increased blood glucose levels. In contrast, mice treated with hrANXA1 have restored phosphorylation of GSK-3 $\beta$ ; allowing for the enzymatic conversion of glucose to glycogen.

We demonstrate using extracellular flux assay that hyperglycemia alter mitochondrial function resulting in the production of excessive protons, that can lead to the production of excessive ROS, which primarily damage the mitochondria. Here we shown that hrANXA1 protects the mitochondria from the detrimental effects of hyperglycemia **in an FPR2-dependent manner**. Consistent with previous *in vivo* data (6) we show that the treatment of human hepatocytes grown in under high glucose with hrANXA1 attenuates the activation of MAPK and restores Akt and GSK-3 $\beta$  activity. Incubation of HEPG2 cells with normal (5.5 mM) results in co-localization of ANXA1 and FPR2 on the plasma membrane. In contrast, treatment of these cells with high glucose (25mM) results in a clear separation of the localization of ANXA1 and FPR2 (Figure 9). Such data further clearly suggests that high glucose conditions effects ANXA1 distribution and its inability to work in an autocrine way (39).

Insulin resistance results in the development of microvascular complications including diabetic nephropathy. ANXA1<sup>-/-</sup> mice fed a HFD have more severe renal dysfunction (proteinuria and a reduction in GFR) when compared to WT mice fed on a HFD diet. Patients with T2D display endothelial dysfunction, which is associated with an increased cardiovascular risk (40). Several lines of evidence suggest that decreased endothelial nitric oxide synthase (eNOS) phosphorylation is a molecular mechanism linking aberrant metabolism and vascular dysfunction: (i) eNOS phosphorylation is diminished in diabetes, hypercholesterolemia, and atherosclerosis (41),(42),(43), (ii) anti-diabetic drugs including statins and PPAR agonists increase eNOS phosphorylation (38), and (iii) signaling molecules including insulin, IGF-1 and leptin increase eNOS phosphorylation (40). Here we demonstrate that mice fed on a HFD have decreased eNOS phosphorylation (in the kidney), which was restored by hrANXA1 treatment. The present study shows that mice fed a HFD have decreased Akt and eNOS activity, while both of these signaling events are attenuated by treatment with hrANXA1. Indeed, inhibition of RhoA/ROCK by statins or other selective inhibitors leads to the up regulation and activation of eNOS (44), potentially through restoration of Akt signaling (40). We also demonstrate that inhibition of RhoA

attenuates the activity of MYTP1. MYPT1 is a key regulator of vascular tone within vascular smooth muscle. Activated (phosphorylated) MYPT1 actively phosphorylates myosin delaying its ability to relax, therefore, inducing prolonged contraction (45),(46) suggesting there could be a link between ANXA1 and the development of hypertension (however this warrants further investigation).

We report here for the first time that plasma levels of ANXA1 are also elevated in patients with T2D, thus supporting the hypothesis that increased circulating ANXA1 levels are indicative of an immune-metabolic state. Obesity is one of the strongest etiological predictors for developing T2D and of adverse cardiovascular outcomes. Here we clearly demonstrate a positive correlation between increased hepatic steatosis (fatty liver index), waist circumference (Table 1) and elevated plasma ANXA1 levels (Figure 1A); suggesting that high ANXA1 levels may also be a biomarker of the development of fatty liver disease (although this hypothesis warrants further investigation). Dyslipidemia is a key predictive factor for both the development of T2D and adverse cardiovascular events. Here we show for the first time a strong positive correlation between elevated total cholesterol and LDL-C and elevated plasma ANXA1 levels. Critically, ANXA1 levels were not correlated with CRP and marker of chronic inflammation. This is consistent with our previous finding showing that ANXA1 levels did not correlate with CRP in patients with type-1 diabetes. We hypothesize that ANXA1 is released from cellular stores into the circulation in response to an aberrant physiological conditions (6) where it is known to signal in both an autocrine and paracrine manner through Formyl-Peptide receptors to elicit both anti-inflammatory and tissue protective effects (5). Two independent lines of evidence support this 1) ANXA1 levels are elevated in both patients and mice with T2D and 2) tissue levels of ANXA1 are decreased in HFD-fed mice (Figure 1) suggesting it has been released from intracellular stores.

## Conclusions

In conclusion, we report here for the first time that mice fed a HFD develop insulin resistance, while endogenous ANXA1 dampens the development of both the diabetic phenotype and the associated hepatic steatosis and nephropathy (proteinuria). Most notably, treatment with hrANXA1 re-establishes normal insulin signaling and attenuates the development of hepatosteatosis and diabetic nephropathy. ANXA1

regulates and inhibits RhoA activity *in vivo*. In murine diabetic tissues, expression of ANXA1 is decreased allowing for the activation of RhoA, while treatment with hrANXA1 inhibits RhoA activity, decreases insulin resistance and restores Akt and eNOS signaling. Finally, we demonstrate that patients with T2D have elevated plasma levels of ANXA1. Thus, we propose that elevated levels of ANXA1 may represent a novel biomarker for the development of hepatosteatosis and that hrANXA1 or its peptide mimetics may be useful in the treatment of T2D and/or its complications.

**Conflict of interests:** The authors declare that they don't have any conflict of interest

### **Author Contributions**

All authors made substantial contributions to conception and design, acquisition of data and interpretation of data; GP, MC, AB, GDN CT and ES drafted the manuscript and provided important intellectual content. FC, DC, AC, RM, MA and JC acquired data on signaling; MB and MHS acquired Elisa data; LG, ALC and CR provided human sample collection and clinical data set and discussion; CR expressed and purified the human recombinant ANXA1, MY contributed to discussion. GP, CT and ES are the guarantors of this work. All authors reviewed and approved the manuscript.

Gareth Purvis and Massimo Collino contributed equally to this work  
and

Egle Solito and Christoph Thiemermann contributed equally to this work.

### **Funding:**

We would like to thank the following funding bodies for their support: the British Heart Foundation (Award number: FS/13/58/30648) to GP and (Award number: 16/60/32739) to MS; University of Turin (Ricerca Locale Linea B 2015 and Linea A 2016) to MC; the William Harvey Research Foundation to CT; Bart's and The London Charity Centre of Diabetic Kidney Disease (programme grant: 577/2348) to CT; and to FISM Fondazione Italiana Sclerosi Multipla (Cod. 2014/R/21) to ES. The work of the authors is supported by: Fondazione Cariplo [2015-0524] and [2015-0564] (ALC) and [2016-0852] (GDN); H2020 REPROGRAM [PHC-03-2015/667837-2] (ALC); Telethon Foundation [GGP13002] (GDN); Ministero della Salute [GR-2011-02346974] (GDN); Aspire Cardiovascular Grant [2016-WI218287] (GDN). The authors declare no conflict of interest relevant to this paper.

### **Acknowledgements**

Parts of the study were presented as a poster presentation at Experimental Biology 17, Chicago, U.S.A, where the work won a research recognition award from the American Society of Physiology – Renal Section.

## References

1. Dai W, Ye L, Liu A, Wen SW, Deng J, Wu X, Lai Z. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. *Medicine (Baltimore)* (2017) **96**:e8179. doi:10.1097/MD.00000000000008179
2. Rhee CM, Ahmadi S-F, Kalantar-Zadeh K. The dual roles of obesity in chronic kidney disease. *Curr Opin Nephrol Hypertens* (2016) **25**:208–216. doi:10.1097/MNH.0000000000000212
3. Mandviwala T, Khalid U, Deswal A. Obesity and Cardiovascular Disease: a Risk Factor or a Risk Marker? *Curr Atheroscler Rep* (2016) **18**:21. doi:10.1007/s11883-016-0575-4
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature* (2001) **414**:813–820. doi:10.1038/414813a
5. Perretti M, D'Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. *Nat Rev Immunol* (2009) **9**:62–70. doi:10.1038/nri2470
6. Purvis GSD, Chiazza F, Chen J, Azevedo-Loiola R, Martin L, Kusters DHM, Reutelingsperger C, Fountoulakis N, Gnudi L, Yaqoob MM, et al. Annexin A1 attenuates microvascular complications through restoration of Akt signalling in a murine model of type 1 diabetes. *Diabetologia* (2017) doi:10.1007/s00125-017-4469-y
7. Cristante E, McArthur S, Mauro C, Maggioli E, Romero IA, Wylezinska-Arridge M, Couraud PO, Lopez-Tremoleda J, Christian HC, Weksler BB, et al. Identification of an essential endogenous regulator of blood-brain barrier integrity, and its pathological and therapeutic implications. *Proc Natl Acad Sci U S A* (2013) **110**:832–41. doi:10.1073/pnas.1209362110
8. Biro M, Munoz MA, Weninger W. Targeting Rho-GTPases in immune cell migration and inflammation. *Br J Pharmacol* (2014) **171**:5491–506. doi:10.1111/bph.12658
9. Peng F, Wu D, Gao B, Ingram AJ, Zhang B, Chorneyko K, McKenzie R, Krepinsky JC. RhoA/Rho-Kinase Contribute to the Pathogenesis of Diabetic Renal Disease. *Diabetes* (2008) **57**: Available at: <http://diabetes.diabetesjournals.org/content/57/6/1683#ref-11> [Accessed May 12, 2017]
10. Norata GD, Garlaschelli K, Ongari M, Raselli S, Grigore L, Catapano AL.



- Alberico L. Catapano Thickness Effects of Fractalkine Receptor Variants on Common Carotid Artery Intima-Media Effects of Fractalkine Receptor Variants on Common Carotid Artery Intima-Media Thickness. *Stroke* (2006) **37**:1558–1561. doi:10.1161/01.STR.0000221803.16897.22
11. Basevi V, Di Mario S, Morciano C, Nonino F, Magrini N. Comment on: American Diabetes Association. Standards of Medical Care in Diabetes--2011. *Diabetes Care* 2011;34(Suppl. 1):S11-S61. *Diabetes Care* (2011) **34**:e53–e53. doi:10.2337/dc11-0174
  12. Baragetti A, Norata GD, Sarcina C, Rastelli F, Grigore L, Garlaschelli K, Uboldi P, Baragetti I, Pozzi C, Catapano AL. High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. *J Intern Med* (2013) **274**:252–62. doi:10.1111/joim.12081
  13. Baragetti A, Balzarotti G, Grigore L, Pellegatta F, Guerrini U, Pisano G, Fracanzani AL, Fargion S, Norata GD, Catapano AL. PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans. *Eur J Prev Cardiol* (2017) **24**:1870–1877. doi:10.1177/2047487317724342
  14. HANNON R, CROXTALL JD, GETTING SJ, ROVIEZZO F, YONA S, PAUL-CLARK MJ, GAVINS FNE, PERRETTI M, MORRIS JF, BUCKINGHAM JC, et al. Aberrant inflammation and resistance to glucocorticoids in annexin 1<sup>-/-</sup> mouse. *FASEB J* (2003) **17**:253–255. doi:10.1096/fj.02-0239fje
  15. Kusters DHM, Chatrou ML, Willems BAG, De Saint-Hubert M, Bauwens M, van der Vorst E, Bena S, Biessen EAL, Perretti M, Schurgers LJ, et al. Pharmacological Treatment with Annexin A1 Reduces Atherosclerotic Plaque Burden in LDLR<sup>-/-</sup> Mice on Western Type Diet. *PLoS One* (2015) **10**:e0130484. doi:10.1371/journal.pone.0130484
  16. GOULDING N, Godolphin JL, Sharland PR, Maddison PJ, Sampson M, Peers SH, Flower RJ. Anti-inflammatory lipocortin 1 production by peripheral blood leucocytes in response to hydrocortisone. *Lancet* (1990) **335**:1416–1418. doi:10.1016/0140-6736(90)91445-G
  17. Peng F, Wu D, Gao B, Ingram AJ, Zhang B, Chorneyko K, McKenzie R, Krepinsky JC. RhoA/Rho-Kinase Contribute to the Pathogenesis of Diabetic Renal Disease. *Diabetes* (2008) **57**:
  18. White MF. The IRS-1 signaling system. *Curr Opin Genet Dev* (1994) **4**:47–54. doi:10.1016/0959-437X(94)90090-6

19. Chiazza F, Couturier-Maillard A, Benetti E, Mastrocola R, Nigro D, Cutrin JC, Serpe L, Aragno M, Fantozzi R, Ryffel B, et al. Targeting the NLRP3 Inflammasome to Reduce Diet-Induced Metabolic Abnormalities in Mice. *Mol Med* (2015) **21**:1. doi:10.2119/molmed.2015.00104
20. Gual P, Le Marchand-Brustel Y, Tanti J-F. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. *Biochimie* (2005) **87**:99–109. doi:10.1016/j.biochi.2004.10.019
21. Agard C, Rolli-Derkinderen M, Dumas-de-La-Roque E, Rio M, Sagan C, Savineau JP, Loirand G, Pacaud P. Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension. *Br J Pharmacol* (2009) **158**:1285–94. doi:10.1111/j.1476-5381.2009.00445.x
22. Stephenne X, Foretz M, Taleux N, van der Zon GC, Sokal E, Hue L, Viollet B, Guigas B. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. *Diabetologia* (2011) **54**:3101–10. doi:10.1007/s00125-011-2311-5
23. Kanda T, Wakino S, Homma K, Yoshioka K, Tatematsu S, Hasegawa K, Takamatsu I, Sugano N, Hayashi K, Saruta T. Rho-kinase as a molecular target for insulin resistance and hypertension. (2005) doi:10.1096/fj.05-4197fje
24. Kikuchi Y, Yamada M, Imakiire T, Kushiyaama T, Higashi K, Hyodo N, Yamamoto K, Oda T, Suzuki S, Miura S. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. *J Endocrinol* (2007) **192**:595–603. doi:10.1677/JOE-06-0045
25. Arita R, Hata Y, Nakao S, Kita T, Miura M, Kawahara S, Zandi S, Almulki L, Tayyari F, Shimokawa H, et al. Rho Kinase Inhibition by Fasudil Ameliorates Diabetes-Induced Microvascular Damage. *Diabetes* (2009) **58**:215–226. doi:10.2337/db08-0762
26. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. *Arterioscler Thromb Vasc Biol* (2001) **21**:1712–9. doi:10.1161/HQ1101.098486
27. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Pleiotropic Effects of Statins: Lipid Reduction and Beyond. *J Clin Endocrinol Metab* (2002) **87**:1451–1458. doi:10.1210/jcem.87.4.8412
28. Cordle A, Koenigsknecht-Talboo J, Wilkinson B, Limpert A, Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. *J Biol*

- Chem* (2005) **280**:34202–9. doi:10.1074/jbc.M505268200
29. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. *J Am Soc Nephrol* (2006) **17**:2006–16. doi:10.1681/ASN.2006010012
  30. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ROCK Signaling Ameliorates Progression of Diabetic Nephropathy Independent of Glucose Control. *Diabetes* (2008) **57**:714–723. doi:10.2337/db07-1241
  31. Cantley LC. The Phosphoinositide 3-Kinase Pathway. *Science* (80- ) (2002) **296**:1655–1657. doi:10.1126/science.296.5573.1655
  32. Chen J, Kieswich JE, Chiazza F, Moyes AJ, Gobbetti T, Purvis GSD, Salvatori DCF, Patel NSA, Perretti M, Hobbs AJ, et al. IκB Kinase Inhibitor Attenuates Sepsis-Induced Cardiac Dysfunction in CKD. *J Am Soc Nephrol* (2017) **28**:94–105. doi:10.1681/ASN.2015060670
  33. Khan AI, Coldewey SM, Patel NSA, Rogazzo M, Collino M, Yaqoob MM, Radermacher P, Kapoor A, Thiernemann C. Erythropoietin attenuates cardiac dysfunction in experimental sepsis in mice via activation of the β-common receptor. *Dis Model Mech* (2013) **6**:1021–30. doi:10.1242/dmm.011908
  34. Yamada N, Martin LB, Zechendorf E, Purvis GSD, Chiazza F, Varrone B, Collino M, Shepherd J, Heinbockel L, Gutschmann T, et al. Novel Synthetic, Host-defense Peptide Protects Against Organ Injury/Dysfunction in a Rat Model of Severe Hemorrhagic Shock. *Ann Surg* (2017) **1**. doi:10.1097/SLA.0000000000002186
  35. Sordi R, Nandra KK, Chiazza F, Johnson FL, Cabrera CP, Torrance HD, Yamada N, Patel NSA, Barnes MR, Brohi K, et al. Artesunate Protects Against the Organ Injury and Dysfunction Induced by Severe Hemorrhage and Resuscitation. *Ann Surg* (2017) **265**:408–417. doi:10.1097/SLA.0000000000001664
  36. Qin C, Buxton KD, Pepe S, Cao AH, Venardos K, Love JE, Kaye DM, Yang YH, Morand EF, Ritchie RH. Reperfusion-induced myocardial dysfunction is prevented by endogenous annexin-A1 and its N-terminal-derived peptide Ac-ANX-A1<sub>2-26</sub>. *Br J Pharmacol* (2013) **168**:238–252. doi:10.1111/j.1476-5381.2012.02176.x
  37. Facio FN, Sena AA, Araújo LP, Mendes GE, Castro I, Luz MAM, Yu L, Oliani SM, Burdmann EA. Annexin 1 mimetic peptide protects against renal

- ischemia/reperfusion injury in rats. *J Mol Med* (2011) **89**:51–63. doi:10.1007/s00109-010-0684-4
38. Locatelli I, Sutti S, Jindal A, Vacchiano M, Bozzola C, Reutelingsperger C, Kusters D, Bena S, Parola M, Paternostro C, et al. Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice. *Hepatology* (2014) **60**:531–44. doi:10.1002/hep.27141
  39. McArthur S, Yazid S, Christian H, Sirha R, Flower R, Buckingham J, Solito E. Annexin A1 regulates hormone exocytosis through a mechanism involving actin reorganization. *FASEB J* (2009) **23**:4000–4010. doi:10.1096/fj.09-131391
  40. Huang PL. eNOS, metabolic syndrome and cardiovascular disease. *Trends Endocrinol Metab* (2009) **20**:295–302. doi:10.1016/j.tem.2009.03.005
  41. Li Q, Atochin D, Kashiwagi S, Earle J, Wang A, Mandeville E, Hayakawa K, d'Uscio L V., Lo EH, Katusic Z, et al. Deficient eNOS Phosphorylation Is a Mechanism for Diabetic Vascular Dysfunction Contributing to Increased Stroke Size. *Stroke* (2013) **44**:3183–3188. doi:10.1161/STROKEAHA.113.002073
  42. Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ. Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. *J Biol Chem* (1999) **274**:32512–9. doi:10.1074/JBC.274.45.32512
  43. Ponnuswamy P, Schrötle A, Ostermeier E, Grüner S, Huang PL, Ertl G, Hoffmann U, Nieswandt B, Kuhlencordt PJ. eNOS Protects from Atherosclerosis Despite Relevant Superoxide Production by the Enzyme in apoE<sup>-/-</sup> Mice. *PLoS One* (2012) **7**:e30193. doi:10.1371/journal.pone.0030193
  44. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. *Circ Res* (2005) **97**:1232–5. doi:10.1161/01.RES.0000196564.18314.23
  45. Lee JH, Palaia T, Ragolia L. Impaired insulin-stimulated myosin phosphatase Rho-interacting protein signaling in diabetic Goto-Kakizaki vascular smooth muscle cells. *doi.org* (2012) **302**:C1371–C1381. doi:10.1152/ajpcell.00254.2011
  46. Schefold JC, Filippatos G, Hasenfuss G, Anker SD, von Haehling S. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. *Nat Rev Nephrol* (2016) **12**:610–623. doi:10.1038/nrneph.2016.113

**Table 1: Detail of patients included in the study**

Number of patients per group, age, gender, fasting glucose, Hb1Ac, BMI, waist circumference serum, cholesterol, HDL, LDL-C, triglyceride, C-reactive protein (CRP), ALT, AST, GGT, FLI, creatinine, GFR and urinary albumin. Experimental groups: Normoglycemic (n=30) and patients with type-2 diabetes (T2D, (n=65). Data analyzed by unpaired Student's t-test (normally distributed data) or Mann Whitney U test (data that are not normally distributed) and expressed as mean  $\pm$  SEM. \* =  $p < 0.05$ ; NA= data not available.

	Normoglycemic			T2D		
<b>Number (n)</b>	30			65		
<b>Age (years)</b>	71	$\pm$	0.4	69	$\pm$	0.9
<b>Gender (F %)</b>	13 (43)			46 (35)		
<b>Fasting glucose (mg/dL)</b>	101.3	$\pm$	1.2	171.7	$\pm$	5.6*
<b>Hb1Ac (%)</b>	N/A			7.37	$\pm$	0.1
<b>BMI (kg/m<sup>2</sup>)</b>	26.3	$\pm$	0.6	31.4	$\pm$	0.8*
<b>Waist Circumference</b>	91.3	$\pm$	1.5	105.91	$\pm$	1.74*
<b>Total cholesterol (mg/dL)</b>	189.5	$\pm$	4.8	187.27	$\pm$	5.48
<b>HDL-C (mg/dL)</b>	59.7	$\pm$	1.7	48.02	$\pm$	1.85*
<b>LDL-C (mg/dL, Friedewald)</b>	109.7	$\pm$	4.3	109.61	$\pm$	4.70
<b>Triglycerides (mg/dL)</b>	100.1	$\pm$	5.3	148.26	$\pm$	17.4*
<b>C-Reactive Protein (mg/dL)</b>	0.12	$\pm$	0.02	0.58	$\pm$	0.2*

<b>Alanine Aminotransferase (ALT)</b> (U/L)	19.54	$\pm$ 0.96	31.89	$\pm$ 4.8*
<b>Aspartate Aminotransferase (AST)</b> (U/L)	24.08	$\pm$ 0.61	26.71	$\pm$ 3.1*
<b>Gamma Glutamyl Transpeptidase (GGT)</b> (U/L)	28.6	$\pm$ 3.15	35.16	$\pm$ 2.7*
<b>Fatty Liver Index (%)</b>	37.1	$\pm$ 5.7	66.14	$\pm$ 3.31*
<b>Creatinine</b> (mg/dL)	0.9	$\pm$ 0.04	1.8	$\pm$ 0.1*
<b>GFR</b> (mL/min)	71.3	$\pm$ 2.34	29.7	$\pm$ 1.8*
<b>Urinary albumin</b> (mg/g urinary protein)	N/A		202.0	$\pm$ 48.1

**Table 2: Animals biochemistry**

Body weight gain from baseline, epididymal fat weight, inguinal fat weight, blood glucose, serum insulin and OGTT AUC were measured in WT C57BL/6 or ANXA1<sup>-/-</sup> mice fed a standard diet (chow) or a high-fat diet (HFD) for 10 weeks. HFD-mice were treated with either vehicle or human recombinant (hr) ANXA1 (40 µg/kg, i.p.) five times per weeks between weeks 4 and 10. Data are expressed as mean± SEM of 7-10 mice per group. Data were analyzed by a one-way ANOVA followed by a Bonferroni *post-hoc* test, \*p< 0.05 vs. WT + HFD or <sup>s</sup>p<0.05 vs, ANXA1 + HFD.

	Wild Type				ANXA1 -/-		
	Chow	Chow + hrANXA1	HFD+ Vehicle	HFD + hrANXA1	Chow	HFD + Vehicle	HFD + hrANXA1
Body weight (g)	9.790±0.602*	9.857±0.674*	16.81±0.479	12.87±0.455*	4.550±0.276 <sup>\$</sup>	13.89±0.772	7.00±0.447 <sup>\$</sup>
Epididymal fat (mg)	1.963±0.163*	2.100±0.255*	3.570±0.291	2.867±0.253*	2.288±0.067 <sup>\$</sup>	5.609±0.246	4.361±0.007 <sup>\$</sup>
Inguinal fat (mg)	1.250±0.128*	1.275±0.149*	2.320±0.243	1.833±0.212*	0.714±0.051 <sup>\$</sup>	1.842±0.096	1.370±0.094 <sup>\$</sup>
Blood glucose (mmol/L)	8.438±0.541*	7.682±0.29*	13.86±0.6621	9.088±0.442*	8.650±0.493 <sup>\$</sup>	19.56±1.224	8.483±0.541 <sup>\$</sup>
Serum Insulin (ng/mL)	6.6941.282*	7.110±1.061*	18.73±2.454	7.860±0.697*	5.321±0.238 <sup>\$</sup>	20.54±1.271	13.47±0.817 <sup>\$</sup>
OGTT (AUC)	84.42±4.506*	84.96±3.659*	110.7±3.659	89.42±0.999*	87.65±4.716 <sup>\$</sup>	127.6±3.767	99.93±3.560 <sup>\$</sup>



## Legend to figures

### Figure 1. Assessment of ANXA1 levels in patients with type-2 diabetes.

(A) Plasma ANXA1 levels measured by ELISA in age and sex match normoglycemic (n=30) and patients with type-2 diabetes (n=65). (B) Correlation in diabetic patients of plasma ANXA1 levels and: Fatty Liver (B), LDL-C (C), and total cholesterol (D). Data is expressed as mean $\pm$  SEM., \*\*\*\*p< 0.0001. (B-D) 95 % confidence intervals are displayed of the microvascular and significance estimated using Fishers F test p<0.05 was deemed significant.

### Figure 2. Correlation data of clinical markers in patients with type-2 diabetes and ANXA1.

(A) Correlation of plasma CRP with BMI in diabetic patients. (B) Correlation of plasma ANXA1 levels with BMI in diabetic patients. (C) Correlation of plasma ANXA1 levels with CRP in diabetic patients. (D) Correlation of CRP with cholesterol in diabetic patients. (E) Correlation of CRP with LDL in diabetic patients. (F) Plasma ANXA1 levels in patients with diabetes  $\pm$  CKD. (A-E) display 95 % confidence intervals are displayed of the linear regression and significance estimated using Fishers F test p<0.05 was deemed significant.

### Figure 3. ANXA1 attenuates the development of obesity and insulin resistance in HFD fed mice.

C57BL/6 or ANXA1<sup>-/-</sup> mice, fed a standard diet (chow) or a high-fat diet (HFD) for 10 weeks, were treated with vehicle or human recombinant (hr) ANXA1 (40  $\mu$ g/kg, i.p.) five times per week between weeks 5 and 10. A) ELISA for ANXA1 levels were measured in serum isolated from whole blood at harvest, (n=6) B) Western blot analysis of kidney, liver and skeletal muscle show a depletion in ANXA1 which was restored by hrANXA1 treatment (n=6/group). C) Serum insulin levels were measured in plasma isolated from whole blood at harvest (n=6-10/group). D) Basal non-fasted blood glucose was measured at week 10 one hour prior to harvest via the tail vein (n=6-10/group). E) Oral glucose tolerance was assessed over 120 min 1 week prior to harvest in WT mice. F) Oral glucose tolerance was assessed over 120 min 1 week prior to harvest in ANXA1<sup>-/-</sup> mice. G) The area under curve (AUC) of OGTT was calculated for respective groups and used for statistical analysis.

Data analyses by a one-way ANOVA followed by a Bonferroni *post-hoc* test and the mean is expressed mean  $\pm$  SEM., \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ ; \$ $p < 0.05$  vs. WT + HFD; \$\$\$ $p < 0.001$  \$\$\$\$ $p < 0.0001$  vs. ANXA1<sup>-/-</sup> + HFD.

**Figure 4. ANXA1 attenuates HFD induced development of peripheral insulin resistance.**

C57BL/6 or ANXA1<sup>-/-</sup> mice, fed a standard diet (chow) or a high-fat diet (HFD) for 10 weeks, were treated with vehicle or human recombinant (hr) ANXA1 (40  $\mu$ g/kg, i.p.) five times per week between weeks 5 and 10. Western blot analysis for Phosphorylation of Ser<sup>307</sup> on IRS-1 in Skeletal muscle (A) or liver (D) and normalized to total IRS-1; for phosphorylation of Ser<sup>473</sup> on Akt in the skeletal muscle (B) and liver (E) and normalized to total Akt; for phosphorylation of Ser<sup>9</sup> on GSK-3 $\beta$  in the skeletal muscle (C) and in the liver (F) and normalized to total GSK-3 $\beta$ . Data were analyzed by a one-way ANOVA followed by a Bonferroni *post-hoc* test and the mean is expressed mean  $\pm$  SEM., \* $p < 0.05$ , \*\*\*\* $p < 0.0001$  vs. WT + HFD; \$ $p < 0.05$  \$\$\$ $p < 0.001$  \$\$\$\$ $p < 0.0001$  vs. ANXA1<sup>-/-</sup> + HFD.

**Figure 5. ANXA1 attenuates induced lipid accumulation, hepatic injury and renal dysfunction.**

C57BL/6 or ANXA1<sup>-/-</sup> mice, fed a standard diet (chow) or a high-fat diet (HFD) for 10 weeks, were treated with vehicle or human recombinant (hr) ANXA1 (40  $\mu$ g/kg, i.p.) five times per week between weeks 5 and 10. Measure of A) Serum triglyceride, B) Serum cholesterol, C) Liver triglyceride, D) Serum aminotransferase (ALT), n=6-8/group. E) 18 h urine samples was collected and renal dysfunction was measured by albumin to creatinine ratio (ACR), n=6-8 per group. F) Creatinine clearance was measured from urinary and serum creatinine, n=6-8 per group. Panel G): representative images of hepatic lipid deposition assessed by Oil Red-O staining. Panel H: representative images of histological changes in kidney structure assessed by periodic acid-Schiff staining, yellow arrows indicating brush borders of proximal tubules.

Data were analyzed by a one-way ANOVA followed by a Bonferroni *post-hoc* test and the mean is expressed mean  $\pm$  SEM., \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$  vs. WT + HFD. \$ $p < 0.05$ , \$\$\$ $p < 0.001$  vs. ANXA1<sup>-/-</sup> + HFD.

**Figure 6. ANXA1 attenuates HFD induction of eNOS in the diabetic kidney**

C57BL/6 or ANXA1<sup>-/-</sup> mice, fed a standard diet (chow) or a high-fat high-sugar diet (HFD) for 10 weeks, were treated with vehicle or hrANXA1 (40 µg/kg, i.p.) five times per weeks between weeks 5 and 10. At harvest kidney, liver and skeletal muscle was harvested. Phosphorylation of eNOS was determined by western blot; a representative blot is shown and densitometry quantification of n=3 independent experiments.

**Figure 7. ANXA1 attenuates RhoA induction in mice fed a HFD.**

C57BL/6 or ANXA1<sup>-/-</sup> mice, fed a standard diet (chow) or a high-fat high-sugar diet (HFD) for 10 weeks, were treated with vehicle or hrANXA1 (40 µg/kg, i.p.) five times per weeks between weeks 5 and 10. At harvest kidney, liver and skeletal muscle was collected. (A-C) Phosphorylation of Ser<sup>188</sup> on RhoA was normalized to total RhoA in kidney (A), liver (B) and skeletal muscle (C). (D-F) Phosphorylation of Thr<sup>853</sup> on MYPT1 was normalized to total MYPT1 in kidney (D), liver (E) and skeletal muscle (F). A representative blot is shown for each protein and densitometry quantification of n=3 experiments represented in the histograms. Data were analyzed by a one-way ANOVA followed by a Bonferroni *post-hoc* test and the mean is expressed mean ± SEM., \*p< 0.05, \*\*p< 0.01, \*\*\*p<0.001, \*\*\*\*p< 0.0001 vs WT + HFD; \$p<0.05, \$\$\$p<0.001, \$\$\$\$p<0.0001 vs. ANXA1<sup>-/-</sup> +HFD.

**Figure 8: ANXA1 protects human hepatocytes from excess proton leak via FPR2.**

HepG2 cells were grown for 48 hours in 5.5 mM glucose, 25 mM glucose, 25 mM glucose + hrANXA1 or 25 mM glucose + hrANXA1 + WRW4. (A) Oxygen consumption rate was assessed using SeaHorse analyzer. (B) Basal OCR, and (C) ATP-linked OCR and (D) proton leak. (E) Expression and localization of FPR2 and ANXA1 assessed by immunofluorescent staining and visualized using image stream. (F) 1x10<sup>6</sup> HepG2 cells were grown in 6 well plates and protein isolated to assess phosphorylation state of 43 proteins using human phospho-proteome profiler. (B-D) Data were analyzed by a one-way ANOVA followed by a Bonferroni *post-hoc* test and the mean is expressed mean ± SEM., \*\*p< 0.01, \*\*\*\*p< 0.0001 vs HepG2 + 25 mM glucose. (F) Data expressed as fold change to HepG2 + 5.5 mM glucose of pooled samples from 3 independent experiments.